However, numerous differences do occur in fundus appearance, the clinical course of the diseases, and electrophysiology. Suspected etiology
One cause of the White Dot Syndromes as suggested by Gass involves viral or infectious agents. Specifically pertaining to the AZOOR complex, Gass has postulated that a virus may enter the retina at the optic head and the infection may spread from one photoreceptor to another. Some unexplained features include the development of more than one disease in the same patient and the majority of cases occurring in females. According to Beckers common genetic hypothesis, "unlike mendelian genetic disorders, common autoimmune and inflammatory diseases arise from combinatorial interactions of common non-disease specific loci, disease specific loci, and specific environmental triggers." An important aspect of this hypothesis pertains to the existence of common non-disease genes that predispose patients to autoimmune diseases. Jampol and Becker insinuate that common susceptibility genes are present in patients affected by white dot syndromes. The presence of environmental triggers, such as viral infections, immunizations, and stress, and interactions with other genes contribute to the development of the white dot syndromes. Additionally, Jampol and Becker hypothesize that the predisposing genetic loci can be identified.Gass points to a lack of evidence in support of the Becker theory. Instead, Gass highlights that although evidence indicates that patients with acute zonal occult outer retinopathy have a greater chance of developing autoimmune diseases, this does not mean that the complex of disorders are autoimmune diseases.
History
Fexinidazole was discovered by the German pharmaceutical company Hoechst AG, but its development as a pharmaceutical was halted in the 1980s. Society and culture
Fexinidazole Winthrop, a Sanofi-Aventis product developed with the Drugs for Neglected Diseases Initiative (DNDi), received a positive endorsement from the European Medicines Agency in 2018, for use in non-European markets. It was approved for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis (HAT) in the Democratic Republic of the Congo (DRC) in December 2018. Fexinidazole was included in the role of honour in Préscrire magazines 2020 prize list. [1]

Veterinary use
Fexinidazole is promising in African animal trypanosomiasis. Torreele et al. 2010 found the drug to be effective against T. b. gambiense infection of mice, rats, rabbits and beagles. They also found no toxicity in any of them, including a lack of mutagenicity despite in vitro mutagenicity. References
External links
"Fexinidazole". Drug Information Portal. U.S. National Library of Medicine.